Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.

Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, Debeljak M, Kamiyama H, Narang A, Laheru DA, Zheng L, Lin MT, Gocke CD, Fishman EK, Hruban RH, Goggins MG, Molenaar IQ, Cameron JL, Weiss MJ, Velculescu VE, He J, Wolfgang CL, Eshleman JR.

Clin Cancer Res. 2019 May 29. pii: clincanres.0197.2019. doi: 10.1158/1078-0432.CCR-19-0197. [Epub ahead of print]

PMID:
31142500
2.

A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study).

Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein PE, Morse MA, Zeh H, Weekes CD, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru DA, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM.

Clin Cancer Res. 2019 May 24. pii: clincanres.2992.2018. doi: 10.1158/1078-0432.CCR-18-2992. [Epub ahead of print]

PMID:
31126960
3.

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.

Karasic TB, O'Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Borazanci E, De Jesus-Acosta A, Redlinger C, Burrell JA, Laheru DA, Von Hoff DD, Amaravadi RK, Drebin JA, O'Dwyer PJ.

JAMA Oncol. 2019 May 23. doi: 10.1001/jamaoncol.2019.0684. [Epub ahead of print]

PMID:
31120501
4.

Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.

Danilova L, Ho WJ, Zhu Q, Vithayathil T, De Jesus-Acosta A, Azad NS, Laheru DA, Fertig EJ, Anders R, Jaffee EM, Yarchoan M.

Cancer Immunol Res. 2019 Jun;7(6):886-895. doi: 10.1158/2326-6066.CIR-18-0822. Epub 2019 May 1.

PMID:
31043417
5.

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.

Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM, Jaffee EM.

JCI Insight. 2019 Mar 21;4(6). pii: 126908. doi: 10.1172/jci.insight.126908. eCollection 2019 Mar 21.

6.

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM.

JCI Insight. 2018 Jul 12;3(13). pii: 122092. doi: 10.1172/jci.insight.122092.

7.

Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients.

Ryan JF, Rosati LM, Groot VP, Le DT, Zheng L, Laheru DA, Shin EJ, Jackson J, Moore J, Narang AK, Herman JM.

Oncotarget. 2018 Mar 27;9(23):16427-16436. doi: 10.18632/oncotarget.24713. eCollection 2018 Mar 27.

8.

Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.

Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, Fishman EK, Hruban RH, Yu J, Burkhart RA, Cameron JL, Weiss MJ, Wolfgang CL, He J.

Ann Surg. 2018 Jun 18. doi: 10.1097/SLA.0000000000002753. [Epub ahead of print]

PMID:
29596120
9.

Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers.

Schunke KJ, Rosati LM, Zahurak M, Herman JM, Narang AK, Usach I, Klein AP, Yeo CJ, Korman LT, Hruban RH, Cameron JL, Laheru DA, Abrams RA.

Adv Radiat Oncol. 2017 Aug 3;3(1):42-51. doi: 10.1016/j.adro.2017.07.008. eCollection 2018 Jan-Mar.

10.

Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.

Herman JM, Jabbour SK, Lin SH, Deek MP, Hsu CC, Fishman EK, Kim S, Cameron JL, Chekmareva M, Laheru DA, Narang AK, Pawlik TM, Hruban RH, Wolfgang CL, Iacobuzio-Donahue CA.

Pancreas. 2018 Feb;47(2):208-212. doi: 10.1097/MPA.0000000000000985.

11.

Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy.

Rao AD, Liu Y, von Eyben R, Hsu CC, Hu C, Rosati LM, Parekh A, Ng K, Hacker-Prietz A, Zheng L, Pawlik TM, Laheru DA, Jaffee EM, Weiss MJ, Le DT, Hruban RH, De Jesus-Acosta A, Wolfgang CL, Narang AK, Chang DT, Koong AC, Herman JM.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):486-489. doi: 10.1016/j.ijrobp.2017.10.001. Epub 2017 Oct 12.

PMID:
29157747
12.

Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective.

Ryan JF, Groot VP, Rosati LM, Hacker-Prietz A, Narang AK, McNutt TR, Jackson JF, Le DT, Jaffee EM, Zheng L, Laheru DA, He J, Pawlik TM, Weiss MJ, Wolfgang CL, Herman JM.

Ann Surg Oncol. 2018 Jan;25(1):280-289. doi: 10.1245/s10434-017-6134-6. Epub 2017 Oct 23.

PMID:
29063299
13.

Targeting neoantigens to augment antitumour immunity.

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM.

Nat Rev Cancer. 2017 Aug 24;17(9):569. doi: 10.1038/nrc.2017.74. No abstract available.

PMID:
28835723
14.

Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.

Shrestha B, Sun Y, Faisal F, Kim V, Soares K, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, Hacker-Prietz A, Chen L, Laheru DA, De Jesus-Acosta A, Le DT, Donehower R, Azad N, Diaz LA, Murphy A, Lee V, Fishman EK, Hruban RH, Liang T, Cameron JL, Makary M, Weiss MJ, Ahuja N, He J, Wolfgang CL, Huang CY, Zheng L.

Cancer Med. 2017 Jul;6(7):1552-1562. doi: 10.1002/cam4.1104. Epub 2017 Jun 21.

15.

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.

Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.

16.

Strategies for Increasing Pancreatic Tumor Immunogenicity.

Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM.

Clin Cancer Res. 2017 Apr 1;23(7):1656-1669. doi: 10.1158/1078-0432.CCR-16-2318. Review.

17.

Targeting neoantigens to augment antitumour immunity.

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM.

Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24. Review. Erratum in: Nat Rev Cancer. 2017 Aug 24;17 (9):569.

18.

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A.

Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2.

19.

Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer.

Rao AD, Sugar EA, Chang DT, Goodman KA, Hacker-Prietz A, Rosati LM, Columbo L, O'Reilly E, Fisher GA, Zheng L, Pai JS, Griffith ME, Laheru DA, Iacobuzio-Donahue CA, Wolfgang CL, Koong A, Herman JM.

Pract Radiat Oncol. 2016 Nov - Dec;6(6):417-424. doi: 10.1016/j.prro.2016.05.005. Epub 2016 May 25.

20.

Metastatic pancreatic adenocarcinoma associated with chronic calcific pancreatitis and a heterozygous SPINK1 N34S mutation.

Moran RA, Klapheke R, Jalaly NY, Makary MA, Hirose K, Goggins M, Wood L, Laheru DA, Lennon AM, Khashab MA, Singh VK.

Pancreatology. 2016 Sep-Oct;16(5):869-72. doi: 10.1016/j.pan.2016.06.006. Epub 2016 Jun 21.

PMID:
27358244
21.

Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.

Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, Hacker-Prietz A, Assadi RK, Saeed AM, Pawlik TM, Jaffee EM, Laheru DA, Tran PT, Weiss MJ, Wolfgang CL, Ford E, Grossman SA, Ye X, Ellsworth SG.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):571-9. doi: 10.1016/j.ijrobp.2015.11.026. Epub 2015 Dec 1.

22.

Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.

Jhaveri DT, Kim MS, Thompson ED, Huang L, Sharma R, Klein AP, Zheng L, Le DT, Laheru DA, Pandey A, Jaffee EM, Anders RA.

Cancer Immunol Res. 2016 Mar;4(3):225-33. doi: 10.1158/2326-6066.CIR-15-0200-T. Epub 2016 Feb 3. Erratum in: Cancer Immunol Res. 2016 May;4(5):472.

23.

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma.

Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL.

Ann Surg. 2016 Dec;264(6):1073-1081.

24.

Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.

Wild AT, Dholakia AS, Fan KY, Kumar R, Moningi S, Rosati LM, Laheru DA, Zheng L, De Jesus-Acosta A, Ellsworth SG, Hacker-Prietz A, Voong KR, Tran PT, Hruban RH, Pawlik TM, Wolfgang CL, Herman JM.

J Gastrointest Oncol. 2015 Apr;6(2):115-25. doi: 10.3978/j.issn.2078-6891.2014.091.

25.

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM.

J Clin Oncol. 2015 Apr 20;33(12):1325-33. doi: 10.1200/JCO.2014.57.4244. Epub 2015 Jan 12.

26.

The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.

Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT, De Jesus-Acosta AM, Hacker-Prietz A, Rosati LM, Assadi RK, Dipasquale S, Pawlik TM, Zheng L, Weiss MJ, Laheru DA, Wolfgang CL, Herman JM.

Ann Surg Oncol. 2015 Jul;22(7):2352-8. doi: 10.1245/s10434-014-4274-5. Epub 2015 Jan 7.

27.

Correlation of clinical stage and performance status with quality of life in patients seen in a pancreas multidisciplinary clinic.

Moningi S, Walker AJ, Hsu CC, Reese JB, Wang JY, Fan KY, Rosati LM, Laheru DA, Weiss MJ, Wolfgang CL, Pawlik TM, Herman JM.

J Oncol Pract. 2015 Mar;11(2):e216-21. doi: 10.1200/JOP.2014.000976. Epub 2015 Jan 6.

28.

Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, Iacobuzio-Donahue CA, Griffith ME, Pawlik TM, Pai JS, O'Reilly E, Fisher GA, Wild AT, Rosati LM, Zheng L, Wolfgang CL, Laheru DA, Columbo LA, Sugar EA, Koong AC.

Cancer. 2015 Apr 1;121(7):1128-37. doi: 10.1002/cncr.29161. Epub 2014 Dec 23.

29.

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.

Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Bigley G, Womack C, Azad NS.

Br J Cancer. 2015 Jan 6;112(1):24-31. doi: 10.1038/bjc.2014.515. Epub 2014 Sep 30.

30.

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.

De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh AJ, Le DT, Caturegli P.

Int J Cancer. 2015 Jan 1;136(1):127-37. doi: 10.1002/ijc.28973. Epub 2014 May 28.

31.

Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.

Dholakia AS, Chaudhry M, Leal JP, Chang DT, Raman SP, Hacker-Prietz A, Su Z, Pai J, Oteiza KE, Griffith ME, Wahl RL, Tryggestad E, Pawlik T, Laheru DA, Wolfgang CL, Koong AC, Herman JM.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):539-46. doi: 10.1016/j.ijrobp.2014.02.031. Epub 2014 Apr 18.

32.

A Phase 2 Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable, Locally Advanced Pancreatic Adenocarcinoma.

Wild AT, Chang DT, Goodman KA, Laheru DA, Zheng L, Raman SP, Columbo LA, Wolfgang CL, Koong AC, Herman JM.

Pract Radiat Oncol. 2013 Apr-Jun;3(2 Suppl 1):S4-5. doi: 10.1016/j.prro.2013.01.016. Epub 2013 Mar 25. No abstract available.

PMID:
24674559
33.

Detection of circulating tumor DNA in early- and late-stage human malignancies.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr.

Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.

34.

Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer.

Fan KY, Dholakia AS, Wild AT, Su Z, Hacker-Prietz A, Kumar R, Hodgin M, Hsu CC, Le DT, De Jesus-Acosta A, Diaz LA Jr, Laheru DA, Hruban RH, Fishman EK, Brown TD, Pawlik TM, Wolfgang CL, Tran PT, Herman JM.

J Natl Compr Canc Netw. 2014 Jan;12(1):50-7.

35.

Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions.

Wild AT, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR, Laheru DA, Le DT, Kumar R, Pai JS, Hargens B, Sharabi AB, Shin EJ, Zheng L, Pawlik TM, Wolfgang CL, Koong AC, Herman JM.

J Gastrointest Oncol. 2013 Dec;4(4):343-51. doi: 10.3978/j.issn.2078-6891.2013.044.

36.

Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships.

Dholakia AS, Hacker-Prietz A, Wild AT, Raman SP, Wood LD, Huang P, Laheru DA, Zheng L, De Jesus-Acosta A, Le DT, Schulick R, Edil B, Ellsworth S, Pawlik TM, Iacobuzio-Donahue CA, Hruban RH, Cameron JL, Fishman EK, Wolfgang CL, Herman JM.

J Radiat Oncol. 2013 Dec;2(4):413-425. doi: 10.1007/s13566-013-0115-6. Epub 2013 Sep 22.

37.

Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design.

Dholakia AS, Kumar R, Raman SP, Moore JA, Ellsworth S, McNutt T, Laheru DA, Jaffee E, Cameron JL, Tran PT, Hobbs RF, Wolfgang CL, Herman JM.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1007-15. doi: 10.1016/j.ijrobp.2013.09.005.

38.

Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.

Herman JM, Fan KY, Wild AT, Wood LD, Blackford AL, Donehower RC, Hidalgo M, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Iacobuzio-Donahue CA, Wolfgang CL.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):458-9. doi: 10.1016/j.ijrobp.2013.06.2039. No abstract available.

39.

Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine.

Schueneman AJ, Sugar EA, Uram J, Bigelow E, Herman JM, Edil BH, Jaffee EM, Zheng L, Laheru DA.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S725-30. doi: 10.1245/s10434-013-3262-5. Epub 2013 Sep 18.

40.

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, Laheru DA.

J Immunother. 2013 Sep;36(7):382-9. doi: 10.1097/CJI.0b013e31829fb7a2.

41.

Recent progress in pancreatic cancer.

Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH.

CA Cancer J Clin. 2013 Sep;63(5):318-48. doi: 10.3322/caac.21190. Epub 2013 Jul 15. Review.

42.

Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.

Herman JM, Fan KY, Wild AT, Hacker-Prietz A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De Jesus-Acosta A, Hidalgo M, Donehower RC, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Wolfgang CL.

Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):678-85. doi: 10.1016/j.ijrobp.2013.03.032.

43.

The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma.

Wild AT, Ye X, Ellsworth SG, Smith JA, Narang AK, Garg T, Campian J, Laheru DA, Zheng L, Wolfgang CL, Tran PT, Grossman SA, Herman JM.

Am J Clin Oncol. 2015 Jun;38(3):259-65. doi: 10.1097/COC.0b013e3182940ff9.

44.

Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.

Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA.

J Clin Oncol. 2013 Mar 1;31(7):886-94. doi: 10.1200/JCO.2012.44.7516. Epub 2013 Jan 22.

45.

Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.

Yachida S, White CM, Naito Y, Zhong Y, Brosnan JA, Macgregor-Das AM, Morgan RA, Saunders T, Laheru DA, Herman JM, Hruban RH, Klein AP, Jones S, Velculescu V, Wolfgang CL, Iacobuzio-Donahue CA.

Clin Cancer Res. 2012 Nov 15;18(22):6339-47. doi: 10.1158/1078-0432.CCR-12-1215. Epub 2012 Sep 18.

46.

Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning.

Qiu H, Wild AT, Wang H, Fishman EK, Hruban RH, Laheru DA, Kumar R, Hacker-Prietz A, Tuli R, Tryggestad E, Schulick RD, Cameron JL, Edil BH, Pawlik TM, Wolfgang CL, Herman JM.

Radiother Oncol. 2012 Aug;104(2):167-72. doi: 10.1016/j.radonc.2012.07.004. Epub 2012 Aug 8.

47.

Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making.

Nathan H, Bridges JF, Cosgrove DP, Diaz LA Jr, Laheru DA, Herman JM, Schulick RD, Edil BH, Wolfgang CL, Choti MA, Pawlik TM.

Ann Surg Oncol. 2012 Nov;19(12):3668-76. doi: 10.1245/s10434-012-2564-3. Epub 2012 Aug 9.

48.

Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.

Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA Jr, Donehower RC, Zhao M, Rudek MA, Messersmith WA.

Invest New Drugs. 2013 Apr;31(2):345-54. doi: 10.1007/s10637-012-9820-z. Epub 2012 May 22.

49.

Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer.

Hsu CC, Wolfgang CL, Laheru DA, Pawlik TM, Swartz MJ, Winter JM, Robinson R, Edil BH, Narang AK, Choti MA, Hruban RH, Cameron JL, Schulick RD, Herman JM.

J Gastrointest Surg. 2012 Apr;16(4):753-61. doi: 10.1007/s11605-011-1811-4. Epub 2012 Feb 7.

50.

Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation.

Rudra S, Narang AK, Pawlik TM, Wang H, Jaffee EM, Zheng L, Le DT, Cosgrove D, Hruban RH, Fishman EK, Tuli R, Laheru DA, Wolfgang CL, Diaz LA Jr, Herman JM.

Pract Radiat Oncol. 2012;2(2):77-85.

Supplemental Content

Loading ...
Support Center